The Middle East & Africa osteoarthritis therapy market was valued at US$ 460.00 million in 2022 and is expected to reach US$ 762.98 million by 2030; it is estimated to register a CAGR of 6.5% from 2022 to 2030.
Also, The World Health Organization report further reveals that, about 73% of are living with OA are older than 55 years and 60% are female. Thus, with the rising prevalence of OA, new therapy options such as biological therapy are gaining attention worldwide. Platelet-rich plasma (PRP) therapy is one example that has emerged as a promising treatment for patients suffering from OA. PRP enhances tissue recovery by catalyzing the body's natural healing and tissue repair processes.
Transcutaneous Electrical Nerve Stimulation (TENS) is another example of a treatment option to treat OA. TENS helps minimize acute and chronic pains by reducing the need for medications. Therefore, rising prevalence of OA accelerates demand for innovative treatment options, reducing the dependency on medications in the coming years.
In South Africa, in urban settings, it accounted for 55.1%; in rural settings, it ranged from 29.5% to 29.7%, reaching up to 82.7% among the population over 65 years. Physicians suggest several therapeutic options to treat osteoarthritis. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Therefore, the availability of treatment options for osteoarthritis is the major factor responsible for the market growth during the 2022-2030.
Rising Prevalence of Osteoarthritis Bolsters Middle East & Africa Osteoarthritis Therapy Market
Globally, OA affects more than 500 million people accounting 7% of the world's population according to the CDC report. It represents a major cause of long-term disability. Additionally, osteoarthritis is also more prevalent among athletes and people who sustain joint injury or trauma. Moreover, it is more prevalent among women, accounting for 60% of global osteoarthritis cases. According to the World Health Organization (WHO) report, osteoarthritis is more prevalent among older population. Also, OA can affect anyone, but the condition is most common in adults over 40 years age.Also, The World Health Organization report further reveals that, about 73% of are living with OA are older than 55 years and 60% are female. Thus, with the rising prevalence of OA, new therapy options such as biological therapy are gaining attention worldwide. Platelet-rich plasma (PRP) therapy is one example that has emerged as a promising treatment for patients suffering from OA. PRP enhances tissue recovery by catalyzing the body's natural healing and tissue repair processes.
Transcutaneous Electrical Nerve Stimulation (TENS) is another example of a treatment option to treat OA. TENS helps minimize acute and chronic pains by reducing the need for medications. Therefore, rising prevalence of OA accelerates demand for innovative treatment options, reducing the dependency on medications in the coming years.
Middle East & Africa Osteoarthritis Therapy Market Overview
Middle East & Africa region is segmented as Saudi Arabia, South Africa, UAE, and the Rest of Middle East & Africa countries. The rising obesity rates, alteration in lifestyles, and dietary patterns are the most influential factors responsible for accelerating demand for osteoarthritis drugs in the Middle East & Africa region. According to the National Institute of Health (NIH) report, osteoarthritis is the most prevalent form of arthritis.In South Africa, in urban settings, it accounted for 55.1%; in rural settings, it ranged from 29.5% to 29.7%, reaching up to 82.7% among the population over 65 years. Physicians suggest several therapeutic options to treat osteoarthritis. Treatment includes non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen. Therefore, the availability of treatment options for osteoarthritis is the major factor responsible for the market growth during the 2022-2030.
Middle East & Africa Osteoarthritis Therapy Market Segmentation
The Middle East & Africa osteoarthritis therapy market is categorized into therapy type, disease indications, end user, and country.- Based on therapy type, the Middle East & Africa osteoarthritis therapy market is segmented into transcutaneous electrical nerve stimulation (TENS), occupational therapy, physical therapy, platelet-rich plasma (PRP) therapy & stromal vascular fraction, prolotherapy, and others. The physical therapy segment held the largest market share in 2022.
- In terms of disease indications, the Middle East & Africa osteoarthritis therapy market is segmented into knee osteoarthritis, spine osteoarthritis, foot and ankle osteoarthritis, shoulder osteoarthritis, hand osteoarthritis, and others. The knee osteoarthritis segment held the largest share of Middle East & Africa osteoarthritis therapy market in 2022.
- Based on end user, the Middle East & Africa osteoarthritis therapy market is categorized into hospitals and clinics, specialty clinics, ambulatory surgical center, homecare, and others. The homecare segment held the largest share of Middle East & Africa osteoarthritis therapy market in 2022.
- By country, the Middle East & Africa osteoarthritis therapy market is segmented into South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa. South Africa dominated the Middle East & Africa osteoarthritis therapy market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. Osteoarthritis Therapy Market Landscape
5. Middle East & Africa Osteoarthritis Therapy Market - Key Market Dynamics
6. Osteoarthritis Therapy Market - Middle East & Africa Market Analysis
7. Middle East & Africa Osteoarthritis Therapy Market Analysis - by Therapy Type
8. Middle East & Africa Osteoarthritis Therapy Market Analysis - by Disease Indication
9. Middle East & Africa Osteoarthritis Therapy Market Analysis - by End User
10. Middle East & Africa Osteoarthritis Therapy Market - Country Analysis
11. Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Estar Technologies Ltd
- Zimmer Biomet Holdings Inc
- DePuy Synthes Inc
- Bioventus Inc
- Omron Healthcare Inc
- Medi GmbH & Co KG